Shridhar G. Iyer, Chao‐Long Chen, Chih‐Chi Wang, Shih‐Ho Wang, Allan M. Concejero, Yueh‐Wei Liu, Chin‐Hsiang Yang, Chee‐Chien Yong, Bruno Jawan, Yu‐Fan Cheng, Hock‐Liu Eng – 30 May 2007 – Liver transplantation (LT) may be indicated in glycogen storage disorders (GSD) when medical treatment fails to control the metabolic problems or when hepatic adenomas develop. We present our institutional experience with living donor LT (LDLT) for children with GSD. A total of 244 patients underwent primary LDLT at our institution from June 1994 to December 2005.

Nimisha K. Parekh, Linda S. Hynan, James De Lemos, William M. Lee, Acute Liver Failure Study Group – 30 May 2007 – Although rare instances of cardiac injury or arrhythmias have been reported in acute liver failure (ALF), overall, the heart is considered to be spared in this condition. Troponin I, a sensitive and specific marker of myocardial injury, may be elevated in patients with sepsis and acute stroke without underlying acute coronary syndrome, indicating unrecognized cardiac injury in these settings.

Silvina E. Yantorno, Walter K. Kremers, Andrés E. Ruf, Julio J. Trentadue, Luis G. Podestá, Federico G. Villamil – 30 May 2007 – Assessment of prognosis in fulminant hepatic failure (FHF) is essential for the need and appropriate timing of orthotopic liver transplantation (OLT). In this study we investigated the prognostic efficacy of King's College criteria, Clichy's criteria, Model for End‐Stage Liver Disease (MELD), and Pediatric End‐Stage Liver Disease (PELD) in 120 consecutive patients with FHF.

George N. Ioannou – 30 May 2007

Ashok Jain, Raman Venkataramanan, Tai Kwong, Ravi Mohanka, Mark Orloff, Peter Abt, Randeep Kashyap, Georgios Tsoulfas, Cindy Mack, Mary Williamson, Pam Batzold, Adel Bozorgzadeh – 30 May 2007 – The bioavailability of mycophenolic acid (MPA) after oral administration of mycophenolate mofetil (MMF) has been reported to be more than 90% in healthy volunteers, and in kidney and thoracic organ transplant patients. Such information is limited in liver transplant (LTx) patients.

John G. O'Grady – 30 May 2007

Oren K. Fix, Nathan M. Bass, Teresa De Marco, Raphael B. Merriman – 30 May 2007 – Moderate to severe portopulmonary hypertension (PPHTN) increases the risks of orthotopic liver transplantation (OLT). Epoprostenol is an effective treatment of PPHTN, but long‐term effects on pulmonary hemodynamics or liver function in PPHTN are poorly defined. We sought to describe the long‐term effects of treatment with or without epoprostenol on pulmonary hemodynamics, liver biochemistries, and survival in patients with moderate to severe PPHTN at a single center.

Dimitrios P. Bogdanos, Christos Liaskos, Albert Pares, Gary Norman, Eirini I. Rigopoulou, Llorenç Caballeria, George N. Dalekos, Juan Rodes, Diego Vergani – 30 May 2007

Ming‐Lung Yu, Chia‐Yen Dai, Wan‐Long Chuang – 30 May 2007

David G. Koch, Lydia Christiansen, John Lazarchick, Robert Stuart, Ira R. Willner, Adrian Reuben – 30 May 2007 – Case series describing posttransplantation lymphoproliferative disorder (PTLD) after liver transplantation (LTx) have been limited in number because of the rarity of the disorder. The prevalence of Epstein‐Barr virus (EBV) infection and its detection, the clinical and histological diversity of disease, and survival have varied.